Overcoming the toxicity hurdles of genetically targeted T cells.
Cancer Immunol Immunother
; 64(1): 123-30, 2015 Jan.
Article
en En
| MEDLINE
| ID: mdl-25488419
ABSTRACT
The recent successes of clinical trials with T cells genetically modified with either clonal T cell receptors or chimeric antigen receptors have also highlighted their potential toxicities. The aim of this focused review was to describe the adverse events observed in these clinical trials and to link them to the complex biology of genetically targeted T cells. Finally, strategies to overcome these toxicities will be proposed and discussed, including the use of suicide genes and other innovative gene therapy strategies.
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Receptores de Antígenos
/
Receptores de Antígenos de Linfocitos T
/
Linfocitos T
/
Ingeniería Genética
/
Inmunoterapia Adoptiva
/
Tratamiento Basado en Trasplante de Células y Tejidos
/
Neoplasias
Límite:
Animals
/
Humans
Idioma:
En
Revista:
Cancer Immunol Immunother
Asunto de la revista:
ALERGIA E IMUNOLOGIA
/
NEOPLASIAS
/
TERAPEUTICA
Año:
2015
Tipo del documento:
Article
País de afiliación:
Italia